An Evaluation of the Efficacy of Selective Alpha-Blockers in the Treatment of Children with Neurogenic Bladder Dysfunction—Preliminary Findings

Paweł Kroll, Ewa Gajewska, Jacek Zachwieja, Magdalena Sobieska and Przemysław Mańkowski
Additional contact information
Paweł Kroll: Pediatric Surgery and Urology Department, Neurourology Unit, Poznań University of Medical Sciences, ul. Szpitalna 27/33, Poznań 60-572, Poland
Ewa Gajewska: Chair for Rheumatology and Rehabilitation, Poznań University of Medical Sciences, ul. 28 Czerwca 135/147, Poznań 61-545, Poland
Jacek Zachwieja: Pediatric Nephrology Department, Poznań University of Medical Sciences, ul. Szpitalna 27/33, Poznań 60-572, Poland
Magdalena Sobieska: Chair for Rheumatology and Rehabilitation, Poznań University of Medical Sciences, ul. 28 Czerwca 135/147, Poznań 61-545, Poland
Przemysław Mańkowski: Pediatric Surgery and Urology Department, Neurourology Unit, Poznań University of Medical Sciences, ul. Szpitalna 27/33, Poznań 60-572, Poland

IJERPH, 2016, vol. 13, issue 3, 1-8

Abstract: The aim of this study was to assess the usefulness of selective ?1-blockers in children with neurogenic urinary tract dysfunctions and increased leak point pressure (LPP). 14 children from age 6 to 16 years with neurogenic urinary tract dysfunctions (neurogenic bladder) and LPP > 40 cm H 2 O were enrolled in the study. All patients received a selective ?1-blocker (doxazosin) for 6–8 weeks with an initial dosage of 0.03 mg/kg. During the observation period the continuation of oral anticholinergics, Clean Intermittent Catheterization (CIC), observation of “urinary dryness” and urinary incontinence periods were recommended. Patients were scheduled for a follow-up visit and urodynamic investigation after 6–8 weeks after the doxazosin therapy was started. In 4 patients, urine leakage occurred at lower pressures; in 9 patients, no significant changes in urine leak point pressures were detected; in 3 patients, there was a significant increase in the bladder capacity; in one patient, deterioration in continence was noted. The differences both in LPP and LPV before and after the treatment were not statistically significant. Our observations are consistent with the conclusions from other studies and showed no evident efficacy of doxazosin in children with neurogenic bladder.

Keywords: neurogenic bladder dysfunction; alpha-blocker; doxazosin; sphincter; urodynamics (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2016
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/13/3/321/pdf (application/pdf)
https://www.mdpi.com/1660-4601/13/3/321/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:13:y:2016:i:3:p:321-:d:65775

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().